US20240360233A1
University of Texas System
The present disclosure provides antibodies and antigen-binding domain compositions capable of binding to thymic stromal lymphopoietin receptor (TSLPR). Also provided are methods of using such antibodies for the treatment of TSLPR-associated cancers (e.g., B-Cell Acute Lymphoblastic Leukemia (B-ALL …